Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-714-1 | CAS number: 853-23-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Exposure related observations in humans: other data
Administrative data
- Endpoint:
- exposure-related observations in humans: other data
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- publication
- Title:
- Oral Dehydroepiandrosterone for Adrenal Androgen Replacement: Pharmacokinetics and Peripheral Conversion to Androgens and Estrogens in Young Healthy Females after Dexamethasone Suppression
- Author:
- ARLT W, JUSTL H-G, CALLIES F, REINCKE M, HUBLER D, OETTEL M, ERNST M, SCHULTE HM, and ALLOLIO B
- Year:
- 1 998
- Bibliographic source:
- J Clinical Endocrinol Metab
Materials and methods
- Endpoint addressed:
- other: Dehydroepiandrosterone pharmacokinetics and conversion to androgens and estrogens in young healthy females
- Principles of method if other than guideline:
- The primary goal of this study was to define the optimum dehydroepiandrosterone (DHEA) dose necessary to restore hormone concentrations in DHEA-deficient women to the normal range. The study investigated the pharmacokinetics and biotransformation of orally administered DHEA in nine young, healthy female volunteers (age 19-30 years) after transient suppression of adrenal steroid synthesis by dexamethasone (4 x 0.5 mg/day for 4 days) and compared the results with baseline hormone secretion in these women. Diurnal blood sampling was performed during the early follicular phase of four subsequent menstrual cycles in a randomized cross-over design. Cycle 1 served as baseline. Preceding the study days during the cycles 2-4, all subjects were pretreated with oral dexamethasone for 4 days. On the study days 2-4, either placebo or 50 or 100 mg DHEA were administered orally at 0900 hours in a randomized order. On all four study days, 24-hour frequent blood sampling was performed. Mean serum concentrations of the following hormones were measured: Cortisol (nmol/L), DHEA (nmol/L), DHEA-sulfate (umol/L), Androstenedione (nmol/L), 5-alpha-androstane-3-alpha,17-beta-diol-17-glucuronide (nmol/L), Testosterone (nmol/L), Dihydrotestosterone (nmol/L), Estrone (pmol/L) and Estriol (pmol/L).
- GLP compliance:
- no
- Remarks:
- GLP compliance is not applicable to a human pharmacokinetics study.
Test material
- Reference substance name:
- Prasterone
- EC Number:
- 200-175-5
- EC Name:
- Prasterone
- Cas Number:
- 53-43-0
- Molecular formula:
- C19H28O2
- IUPAC Name:
- (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
- Test material form:
- solid
- Details on test material:
- white solid
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL (Dehydroepiandrosterone; DHEA)
- Source: Jenapharm (Jena, Germany)
- Purity: Not specified
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of the test material: Not specified
- Solubility and stability of the test substance in the solvent/vehicle: Not applicable
FORM AS APPLIED IN TEST
- 50 mg capsules (mean DHEA content of the capsules was 49.3 +/- 0.20 mg as determined by high performance liquid chromatography (HPLC)
Method
- Ethical approval:
- confirmed and informed consent free of coercion received
- Remarks:
- Before the study, the protocol had been approved by the Ethics Committee of the University of Wuerzburg and written informed consent was obtained from all volunteers.
- Details on study design:
- DETAILS ON HUMAN VOLUNTEERS
- Sex: Female
- No. of Volunteers: Nine
- Age: 19-30 years, mean age 23.3 +/- 4.1 years
- Smoking Status: Eight nonsmoking, one smoking
- Body Mass Index (BMI): 19.5 to 25.1 kg/m2 (mean 22.5 +/- 1.8 kg/m2)
- Hormonal Status: All volunteers were regularly menstruating and had normal baseline serum concentrations of dehydroepiandrosterone-sulfate, androstenedione and testosterone.
- Health Status: All volunteers had normal blood cell counts and normal hepatic and renal function parameters.
DETAILS ON STUDY PROTOCOL
- Study Design: Single-dose, randomized, cross-over design. Nine volunteers were studied during the early follicular phase off four subsequent menstrual cycles. Cycle 1 served as baseline. During cycles 2-4, all subjects were pretreated with oral dexamethasone (4 x 0.5 mg daily for 4 days) to suppress adrenal steroid synthesis. On the study days 2-4, either placebo or 50 or 100 mg DHEA were administered orally at 0900 hours in a randomized order.
- Blood Sampling: On all four study days, 24-hour blood sampling was performed, starting after an overnight fast at 0830 hours and ending at 0900 hours the following day [-30 (0830 hours), 0, 30, 60, 90, 120, and 150 minutes, and 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours].
- Meals: Standardized meals were served at 1030, 1500, and 2100 hours.
DETAILS ON HORMONE ASSAYS
- Hormones Measured: Cortisol (nmol/L), DHEA (nmol/L), DHEA-sulfate (umol/L), Androstenedione (nmol/L), 5-alpha-androstane-3-alpha,17-beta-diol-17-glucuronide (nmol/L), Testosterone (nmol/L), Dihydrotestosterone (nmol/L), Estrone (pmol/L) and Estriol (pmol/L).
- Assays Used: All serum hormones were determined by established specific direct radioimmunoassays (RIAs).
STATISTICAL ANALYSES AND PHARMACOKINETIC PARAMETERS EVALUATED
- Data Reporting: Mean +/- SEM
- Pharmacokinetic Parameters: Maximum serum concentration measured during a study period of a volunteer (Cmax); time at which Cmax occurred (tmax); terminal elimination rate constant; area under the concentration-time curve from 0-12 hours (AUC 0-12 h)
- Statistical Analysis: AUC 0-12 h as well as tmax and Cmax were calculated and compared by ANOVAwith repeated measurements, t-tests, and Wilcoxon signed rank tests for paired samples. Significance was defined as P < 0.05. - Exposure assessment:
- measured
- Details on exposure:
- DHEA (nmol/L) and two of its metabolites, DHEA-sulfate (umol/L) and 5-alpha-androstane-3-alpha,17-beta-diol-17-glucuronide (nmol/L), were measured in serum collected at -30, 0, 30, 60, 90, 120, and 150 minutes, and 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours after oral administration of DHEA.
Results and discussion
- Results:
- DEXAMETHASONE SUPPRESSION
- Dexamethasone induced a significant suppression of serum cortisol (to 8% of baseline), of DHEA (18%), DHEA-sulfate (16%), androstenedione (26%), testosterone (28%), dihydrotestostesone (43%), and estrone (54%).
DHEA AND DHEA-SULFATE PHARMACOKINETICS AFTER ADMINISTRATION OF 50 MG / 100 MG DHEA
Oral administration of 50mg DHEA led to restoration of DHEA-sulfate baseline levels, whereas 100 mg induced supraphysiological concentrations.
- Serum DHEA, AUC 0-12 h (50 mg DHEA): 176.1 +/- 21.2 nmol/L x h
- Serum DHEA, AUC 0-12 h (100 mg DHEA): 317.6 +/- 35.3 nmol/L x h
- Serum DHEA-sulfate, AUC 0-12 h (50 mg DHEA): 121.6 +/- 12.3 umol/L x h
- Serum DHEA-sulfate, AUC 0-12 h (100 mg DHEA): 195.4 +/- 8.9 umol/L x h
- Serum DHEA, Cmax (50 mg DHEA): 26.4 +/- 3.8 nmol/L
- Serum DHEA, Cmax (100 mg DHEA): 62.1 +/- 11.4 nmol/L
- Serum DHEA-sulfate, Cmax (50 mg DHEA): 14.9 +/- 1.4 umol/L
- Serum DHEA-sulfate, Cmax (100 mg DHEA): 25.2 +/- 1.5 umol/L
- Serum DHEA, tmax (50 mg DHEA): 2.5 +/- 2.1 h
- Serum DHEA, tmax (100 mg DHEA): 2.4 +/- 0.4 h
- Serum DHEA-sulfate, tmax (50 mg DHEA): 2.9 +/- 0.9 h
- Serum DHEA-sulfate, tmax (100 mg DHEA): 2.8 +/- 0.5 h
- Serum DHEA, t1/2 (50 mg DHEA): 8.9 +/-3.6 h
- Serum DHEA, t1/2 (100 mg DHEA): 7.6 +/- 2.7 h
- Serum DHEA-sulfate, t1/2 (50 mg DHEA): 13.2 +/- 2.7 h
- Serum DHEA-sulfate, t1/2 (100 mg DHEA): 12.1 +/- 2.8 h
Any other information on results incl. tables
OTHER ANDROGENS
- Serum concentrations of dihydrotestosterone were restored to baseline after 50mg DHEA, whereas baseline testosterone and androstenedione levels were only achieved by administration of 100 mg DHEA.
- 50 mg DHEA induced an increase in serum androstenedione concentrations to levels around 60% of baseline, and 100 mg DHEA induced a further increase (tmax for 50 and 100 mg DHEA, 2.6 +/- 1.5 h and 2.6 +/- 0.7 h, respectively) followed by a decrease to levels paralleling baseline concentrations from 6–24 h.
- tmax (testosterone) for 50 and 100 mg DHEA were 3.6 +/- 2.2 h and 2.6 +/- 0.6 h, respectively.
- tmax (dihydrotestosterone) for 50 and 100 mg DHEA were 1.8 +/- 0.7h and 2.6 +/- 0.8 h, respectively.
ESTROGENS
- Serum concentrations of estrone were restored to baseline after 50mg DHEA. 100 mg DHEA increased estrone to levels significantly above baseline.
Applicant's summary and conclusion
- Conclusions:
- The study concluded that a 50 mg daily dose of DHEA may be a suitable replacement dose in females with adrenal androgen insufficiency. Additionally, the rapid and lasting conversion to potent androgens demonstrated a potential role of DHEA for androgen replacement in females in general (e.g. postmenopausal women). However, the generation of active circulating steroids after DHEA ingestion suggests that DHEA may have possible unfavorable effects in some clinical situations (e.g., hormone-dependent cancer).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.